Protara Therapeutics (NASDAQ:TARA) Insider Sells $118,865.48 in Stock

Protara Therapeutics, Inc. (NASDAQ:TARA) insider Jacqueline Zummo sold 22,598 shares of the company’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $5.26, for a total transaction of $118,865.48. Following the sale, the insider owned 95,961 shares of the company’s stock, valued at approximately $504,754.86. The trade was a 19.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Protara Therapeutics Stock Up 1.4%

Shares of TARA traded up $0.07 during trading hours on Thursday, hitting $5.11. The company had a trading volume of 511,473 shares, compared to its average volume of 1,112,863. The firm has a market cap of $276.37 million, a P/E ratio of -3.87 and a beta of 1.40. The stock’s 50 day moving average price is $6.06 and its 200 day moving average price is $5.57. Protara Therapeutics, Inc. has a 52-week low of $2.77 and a 52-week high of $7.82.

Protara Therapeutics (NASDAQ:TARA) last issued its earnings results on Tuesday, March 10th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.03). On average, research analysts expect that Protara Therapeutics, Inc. will post -3.32 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on TARA. TD Cowen reissued a “buy” rating on shares of Protara Therapeutics in a research note on Tuesday, March 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Protara Therapeutics in a research note on Thursday, January 22nd. JPMorgan Chase & Co. began coverage on shares of Protara Therapeutics in a report on Wednesday, March 4th. They set an “overweight” rating and a $27.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $23.00 price target on shares of Protara Therapeutics in a report on Tuesday, February 10th. Finally, Piper Sandler started coverage on shares of Protara Therapeutics in a research report on Wednesday, January 7th. They issued an “overweight” rating and a $24.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $21.40.

Hedge Funds Weigh In On Protara Therapeutics

Hedge funds have recently made changes to their positions in the business. Quadrature Capital Ltd bought a new position in shares of Protara Therapeutics during the second quarter valued at approximately $35,000. JPMorgan Chase & Co. bought a new position in Protara Therapeutics in the 2nd quarter worth $46,000. Intech Investment Management LLC bought a new position in Protara Therapeutics in the 2nd quarter worth $49,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Protara Therapeutics in the 2nd quarter worth about $53,000. Finally, Persistent Asset Partners Ltd bought a new stake in shares of Protara Therapeutics during the 4th quarter valued at about $57,000. 38.13% of the stock is owned by hedge funds and other institutional investors.

About Protara Therapeutics

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.